Motor Neuron Disease Clinical Trial
Official title:
Comparison of Ultrasound and Videofluoroscopic Imaging Techniques in Diagnosing Oropharyngeal Dysphagia in Neurologically Impaired Subjects
This study will identify clinical signs and symptoms critical for diagnosing swallowing
disorders and will characterize swallowing problems in various patient populations, such as
patients with Parkinson's disease, stroke, post-polio syndrome, multiple sclerosis and other
conditions that cause swallowing abnormalities.
Patients with swallowing difficulties who are enrolled in NIH neurology or speech pathology
protocols may be eligible for this study. Participants will undergo the following
procedures:
1. Oral examination-A neurologist and speech pathologist examine the patient's swallowing
function. The patient is interviewed about difficulties with food intake, chewing and
swallowing during meals.
2. Ultrasound examination-Ultrasound creates image of areas inside the body using sound
waves. With the patient in a sitting position, a 3/4-inch transducer (device for
transmitting and receiving sound waves) is placed under the chin to visualize tongue
movements during swallowing.
3. Modified barium swallow-While standing or sitting, the patient swallows 1/2 teaspoon of
flavored barium (a radioactive substance) six times (a total of 3 teaspoons), while the
tongue and pharynx (tube leading from the mouth to the esophagus) are scanned and
videotaped. The barium is given in three consistencies-thin, medium and thick
(pudding-like).
4. Electromyography-A small plastic strip with wires attached is placed under the
patient's chin. The patient then swallows 1/2 ounce of barium three times in a row, and
the movement of the chin muscles during swallowing is displayed. Patients may also be
asked to swallow 5/8 cup of barium twice; once with the head tilted upward and once
with the head untilted.
Depending on the test results, patients may be asked to return for follow-up study and
monitoring.
Patients with neurological or neuromuscular conditions may be silent aspirators or at risk
for laryngeal penetration or aspiration because of abnormal oropharyngeal functioning and
thus are at risk for aspiration pneumonia and its serious effects. By providing
identification of the components of the abnormal swallow, and comparing swallowing across
tasks, we may avoid aspiration and can instruct patients on preventative or compensatory
swallowing techniques.
We will study the oral, pharyngeal and upper esophageal phases of swallow using both
ultrasonic imaging and videofluoroscopy in patients with neurologic, genetic, systemic, and
neuromuscular conditions. Most of the previous studies of swallowing have utilized only one
diagnostic imaging technique and have thus provided an incomplete swallowing assessment as
each procedure has unique, but limited capabilities for visualizing the anatomy and
physiology of the swallow.
We also plan to compare discrete and continuous swallowing in these populations. While the
motor physiology for discrete swallowing (i.e., single swallow) has been well studied,
little is known about the details of oral, laryngeal, and pharyngeal coordination during
sequential swallowing as a part of continuous drinking--a common event in everyday eating. A
portion of the protocol will study the effects of fast-paced movement sequencing on the
coordination of the tongue, velum, larynx, and pharynx during continuous drinking.
Videofluoroscopy and ultrasound may be paired or used individually to collect data from
normal subjects and patients with known dysphagia while they perform sequential and discrete
swallowing tasks. A number of timing and displacement measurements of the structures
activated during these tasks will be made from the digitized video images of each swallow,
and analyses will be carried out subsequently across tasks and subjects.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02464748 -
Telehealth in Motor Neurone Disease
|
N/A | |
Completed |
NCT00956488 -
Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis
|
Phase 1/Phase 2 | |
Terminated |
NCT00537446 -
Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis
|
N/A | |
Recruiting |
NCT04944940 -
Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
|
||
Recruiting |
NCT03362658 -
Novel MRI Biomarkers for Monitoring Disease Progression in ALS
|
||
Completed |
NCT00714636 -
Cerebrospinal Fluid Repository
|
N/A | |
Completed |
NCT00076687 -
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
|
Phase 2 | |
Completed |
NCT00071435 -
Brain Function in Primary Lateral Sclerosis
|
N/A | |
Completed |
NCT03487263 -
Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease
|
Phase 1 | |
Enrolling by invitation |
NCT05725759 -
Rehabilitation in SOD1 ALS Treated With Tofersen
|
||
Active, not recruiting |
NCT03811301 -
[BrainConnexion] - Neurodevice Phase I Trial
|
N/A | |
Completed |
NCT02469896 -
A Trial of Tocilizumab in ALS Subjects
|
Phase 2 | |
Completed |
NCT02011204 -
Study of Electrical Impedance Myography (EIM) in ALS
|
N/A | |
Completed |
NCT01495390 -
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers
|
N/A | |
Completed |
NCT02870634 -
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
|
Phase 1 | |
Recruiting |
NCT06201650 -
Neurofilament Light Chain in Amyotrophic Lateral Sclerosis
|
||
Active, not recruiting |
NCT04240925 -
Tolerability, Safety and Efficacy of Sigh Breaths During NIMV in Motor Neuron Disease
|
N/A |